Literature DB >> 11350044

Prolonged wild-type p53 protein accumulation and cisplatin resistance.

E M Yazlovitskaya1, R D DeHaan, D L Persons.   

Abstract

The major limitation for the chemotherapeutic use of DNA-damaging agent cisplatin is the development of resistance in initially responsive tumors. One of the main pathways regulating cell survival following DNA damage is the p53 pathway. In this study we compared the cisplatin-induced response of p53 protein and its downstream targets p21WAF-1 and Mdm2 in the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70. A higher dose of cisplatin and a longer exposure time was required to achieve the same level of p53, p21WAF-1, and Mdm2 protein accumulation in the cisplatin-resistant CP70 cells versus cisplatin-sensitive A2780 cells. A significant difference between the two cell lines was observed in cisplatin-induced stabilization of p53 protein. The p53 half-life increased 31-fold in CP70 cells compared to only 6-fold in A2780 cells. In contrast, there was no difference in p21WAF-1 half-life between the two cell lines. These results demonstrate that in A2780 and CP70 cells resistance to cisplatin correlates with prolonged p53 protein stabilization and accumulation. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350044     DOI: 10.1006/bbrc.2001.4849

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.

Authors:  Rachael R Schulte; Amanda G Linkous; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Cancer Lett       Date:  2011-05-28       Impact factor: 8.679

2.  KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.

Authors:  T Jiffar; T Yilmaz; J Lee; E Hanna; A El-Naggar; D Yu; J N Myers; M E Kupferman
Journal:  Oncogene       Date:  2011-03-07       Impact factor: 9.867

Review 3.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

4.  NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner.

Authors:  Eswar Shankar; Chandreyi Basu; Brett Adkins; Wolfram Siede; Alakananda Basu
Journal:  J Mol Signal       Date:  2010-05-10

5.  The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases.

Authors:  Hu Zhu; Hui-Wen Lo
Journal:  Curr Genomics       Date:  2010-06       Impact factor: 2.236

6.  Dumbbell-like Au-Fe3O4 nanoparticles for target-specific platin delivery.

Authors:  Chenjie Xu; Baodui Wang; Shouheng Sun
Journal:  J Am Chem Soc       Date:  2009-04-01       Impact factor: 15.419

7.  Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells.

Authors:  Zhi-Wei Yu; Peng Zhao; Ming Liu; Xin-Shu Dong; Ji Tao; Xue-Qin Yao; Xin-Hua Yin; Yu Li; Song-Bin Fu
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

8.  Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene.

Authors:  Hui-Wen Lo; Lisa Stephenson; Xinyu Cao; Mira Milas; Raphael Pollock; Francis Ali-Osman
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

9.  Human ovarian tumor cells escape γδ T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules.

Authors:  Jingwei Lu; Reeva Aggarwal; Suman Kanji; Manjusri Das; Matthew Joseph; Vincent Pompili; Hiranmoy Das
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

10.  Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Clarisse S Muenyi; Vanessa A States; Joshua H Masters; Teresa W Fan; C William Helm; J Christopher States
Journal:  J Ovarian Res       Date:  2011-06-22       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.